Fresenius Medical Care Deutschland GmbH
Clinical trials sponsored by Fresenius Medical Care Deutschland GmbH, explained in plain language.
A dialysis care provider, subsidiary of Fresenius Medical Care.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New dialysis salt strategy aims to reduce fluid gain and dizziness Results expected Dec 2026 (estimated)
- New blood filter could improve treatment for autoimmune diseases Results expected Dec 2026 (estimated)
- New dialysis tech aims to improve waste removal for kidney patients Results expected Aug 2027 (estimated)
-
Can a Blood-Cleaning device hit its plasma exchange targets?
Disease control OngoingResearchers review past therapeutic plasma exchange treatments performed with the multiFiltratePRO, a device that cleans blood outside the body. The study looks at records from people with autoimmune diseases who weighed at least 40 kg and received this treatment between 2019 and…
Sponsor: Fresenius Medical Care Deutschland GmbH • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Dialysis study pulled before starting: no patients enrolled
Knowledge-focused CancelledThis study was designed to see how changing the amount of fluid, the time it stays in the belly, and the sugar level in the dialysis fluid affects how much fluid is removed during automated peritoneal dialysis. It was meant for adults with chronic kidney disease on dialysis for a…
Sponsor: Fresenius Medical Care Deutschland GmbH • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC